GLPG1690

Status
Phase 3
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

GLPG1690 is a small molecule, selective autotaxin inhibitor which is fully proprietary to Galapagos. Galapagos identified the autotaxin target using its proprietary target discovery platform and developed molecule GLPG1690 as an inhibitor of this target. In the FLORA Phase 2a trial, patients on treatment with GLPG1690 showed improvement in forced vital capacity (FVC) at 12 weeks, with an encouraging safety profile. Galapagos received orphan drug designation for GLPG1690 in IPF from the US Food & Drug Administration (FDA) and European Commission (EC).

GLPG1690 is an investigational drug and its efficacy and safety have not been established.

Study Purpose

The main purpose of this study is to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated (for example if you get any side effects while on study drug).

Find a Clinical Trial

(Note:  Two identically designed studies are taking place simultaneously at different site locations. Click the link and then enter your address to easily locate the ISABELA trial with a site location nearest you.)

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >